# Gilead Sciences, Inc. (GILD) — Q3-2013 Earnings Results

**Report date:** 2013-10-29 (after market close)  
**Sector:** Health Care / Biotechnology  
**Status:** reported  
**Source:** https://earningsnxt.ai/ticker/GILD/earnings/Q3-2013

## Post-Earnings Brief

### Headline

Gilead Sciences Beats on EPS, Stock Down N/A%

### Key Numbers

| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.52 | N/A | +10.64% |
| Revenue | N/A | N/A | N/A |

### Management Commentary

**Tone:** Cautiously Optimistic

Overall, management conveyed a positive outlook regarding their product performance while remaining aware of potential market headwinds.

**Key quotes:**

> Management highlighted the strong performance in their key therapeutic areas.

> They expressed confidence in their pipeline but acknowledged market challenges.

### Guidance Changes

No guidance updates were provided during the call.

### What It Means

Gilead Sciences reported better-than-expected earnings per share, indicating strong operational performance. However, the lack of revenue data and guidance may leave investors cautious. The stock's reaction is currently unavailable, reflecting uncertainty in market sentiment.

---

_AI-assisted analysis from EarningsNxt. Not financial advice. View full page: https://earningsnxt.ai/ticker/GILD/earnings/Q3-2013_